Assessment of Myocardial Fibrosis Using T1-mapping and Extracellular Volume Measurement on Cardiac Magnetic Resonance Imaging for the Diagnosis of Radiation-induced Cardiomyopathy
Overview
Authors
Affiliations
Radiation-induced heart disease (RIHD) is a serious side effect of thoracic radiation therapy (RT) and is associated with significant morbidity and mortality. Radiation-induced cardiomyopathy (RICM) is one of the manifestations of RIHD, which represents with left ventricular (LV) systolic and diastolic dysfunction due to myocardial fibrosis. Although the diagnosis of RIHD is challenging and is generally an exclusion diagnosis, multimodality imaging including echocardiography, cardiac computed tomography and cardiac magnetic resonance (CMR) imaging could help the diagnosis. Herein, we report a case of 70-years-old male, who had been treated with chemo-radiation therapy for early esophageal cancer, was suffered from medically refractory heart failure due to severely reduced LV systolic function and constrictive pericarditis 8 years after chemo-radiation therapy. Although no gadolinium-enhancement (LGE) was detected on CMR, T1 mapping depicted increased extracellular matrix volumes of 45%, which suggested global myocardial fibrosis. Histopathological analysis by endomyocardial biopsy (EBM) revealed marked degeneration of myocytes and interstitial fibrosis, while vacuolation in myocytes which is characteristics of chemotherapy induced cardiomyopathy was not specific by electron microscopy. Therefore, we diagnosed that the present case was likely to the RICM. < RICM is characterized by inflammation followed by the development of a diffuse, patchy interstitial fibrosis of the myocardium, which is usually obtained either by EBM or at autopsy. Native and post-contrast T1-mapping by CMR enables to estimate extracellular volume (ECV), which is believed to be increased as a result of diffuse myocardial fibrosis. The assessment of myocardial fibrosis using ECV should be useful for early detection of myocardial damage due to RT, and which probably taking place of EBM.>.
Quantitative assessment of radiotherapy-induced myocardial damage using MRI: a systematic review.
Omidi A, Weiss E, Trankle C, Rosu-Bubulac M, Wilson J Cardiooncology. 2023; 9(1):24.
PMID: 37202766 PMC: 10193692. DOI: 10.1186/s40959-023-00175-0.
Sharifkazemi M, Elahi M, Sayad M Front Cardiovasc Med. 2023; 10:1020082.
PMID: 37153473 PMC: 10154576. DOI: 10.3389/fcvm.2023.1020082.
Cardiovascular Magnetic Resonance Imaging Patterns in Rare Cardiovascular Diseases.
Markousis-Mavrogenis G, Giannakopoulou A, Belegrinos A, Pons M, Bonou M, Vartela V J Clin Med. 2022; 11(21).
PMID: 36362632 PMC: 9657782. DOI: 10.3390/jcm11216403.
Assessing Silent Cardiotoxicity in Long-Term Lymphoma Survivors Treated With Radiotherapy.
Miller E, Mikrut K, Addison D JACC CardioOncol. 2022; 3(5):707-710.
PMID: 34988479 PMC: 8702787. DOI: 10.1016/j.jaccao.2021.11.003.
Severe Cardiac Toxicity Induced by Cancer Therapies Requiring Intensive Care Unit Admission.
Montisci A, Palmieri V, Liu J, Vietri M, Cirri S, Donatelli F Front Cardiovasc Med. 2021; 8:713694.
PMID: 34540917 PMC: 8446380. DOI: 10.3389/fcvm.2021.713694.